A Multicenter, Prospective, Observational, Open-Label Study of the Safety and Comfort of Gensulin ® Delivery Device Use in a Large Cohort of Adult and Elderly Patients with Type 2 Diabetes

Małgorzata Masierek, Katarzyna Nabrdalik, Hanna Kwiendacz, Tomasz Sawczyn and Janusz Gumprecht
Additional contact information
Małgorzata Masierek: Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland
Katarzyna Nabrdalik: Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland
Hanna Kwiendacz: Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland
Tomasz Sawczyn: Department of Physiology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland
Janusz Gumprecht: Department of Internal Medicine, Diabetology and Nephrology in Zabrze, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Katowice, Poland

IJERPH, 2020, vol. 17, issue 20, 1-9

Abstract: Insulin treatment is necessary for many patients with type 2 diabetes, and its delivery must be safe and comfortable. This study evaluated patients’ safety and comfort when using a Gensulin ® delivery device, GensuPen (Bioton), a reusable insulin pen device for injecting Gensulin ® insulin among adult and elderly patients with type 2 diabetes. This was a 4-week multicenter, prospective, observational, open-label study in patients with diabetes mellitus type 2 who have recently started using a GensuPen. Overall, 10,309 patients (mean age: 63 ± 12.0 years; 47.9% female) were analyzed in this study. Of these, 2.5% had used an insulin delivery device before, and for 97.5%, GensuPen was the first delivery device they had used. Most (87.8%) of the patients rated the GensuPen as very good in setting the dose, 92.0% in confirmation of successful insulin administration, 80.9% in trigger location, and 75.0% in force needed for injection. The overall safety of the GensuPen use was high since severe hypoglycemia occurred only in 0.2% of the studied patients. There were 0.6% adverse events, none of which were serious. This real-life observation data shows that the GensuPen was well accepted and safe in this large patient population of adult and elderly patients with type 2 diabetes.

Keywords: diabetes mellitus type 2; insulin pen; safety; satisfaction (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/20/7587/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/20/7587/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:20:p:7587-:d:430940

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().